Biocon Biologics is continuing to rack up the capital needed to close its multi-billion deal for Viatris’ global biosimilars business, with two quick equity investments from parent Biocon Limited as stipulated under its acquisition agreement.

Genfit CEO Pascal Prigent talks to Scrip about the company's high-profile trial failure in NASH and the pipeline pivot to various other drug candidates for rare liver diseases.

Syngene’s COO, Mahesh Bhalgat, said the firm is better placed than some peers to serve clients for biologics-based advanced therapies and address the cost element for new modalities like mRNA. He also outlines the research, development and manufacturing services company's capabilities in oligonucleotide-based therapeutics, an area that's seeing growing interest.

Biocon, which is set to close its deal with Viatris shortly, says it is in a “very good position” to vie for a share of the adalimumab biosimilar pie in the US and has had encouraging preliminary discussions with payers.